Korean new drug cash cows bring in KRW 100 bil in 3 quarters
By Chon, Seung-Hyun | translator Kim, Jung-Ju
23.10.19 06:20:07
가나다라
0
Cumulative rank of outpatient drug prescriptions in Q3... Lipitor maintains overall lead
Rosuzet's prescriptions amounted to KRW 130.9 billion as of September...Chasing Lipitor's quarterly prescription sales by KRW 2.7 billion
K-CAB’s sales exceed KRW 100 billion for 3 consecutive years...Gliatamine also exceeds KRW 100 billion in 3 quarters
Domestically developed drugs are continuing to show strong performance in high ranks in Korea’s outpatient prescriptions market. Prescriptions of Hanmi Pharm’s combination new drug Rosuzet and HK Inno.N's K-CAB have exceeded KRW 100 billion in just 3 quarters. Daewoong Bio's brain function enhancer Gliatamin also performed well.
According to the market research institution UBIST on the 19th, Viatris’s hyperlipidemia treatment, Lipitor, recorded the highest cumulative outpatient prescription amount of KRW 146.8 billion in Q3 this year. Although it decreased by 2.6% compared to the same period last year, it maintained its leading position.
Lipitor, which was introduced to the do
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)